Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | THRA | P10827 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | TTR | P02766 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23964667 | 0.81 | SIRT5 (0.55) | SIRT5CYP2C9CYP2C19HIF1ATHRB | |
| SCHEMBL10024350 | 0.81 | KDM6B (0.53) | SIRT5CYP2C9CYP2C19HIF1AKDM6B | |
| SCHEMBL11229260 | 0.80 | KDM6B (0.72) | CYP2C9HIF1AKDM6BTHRBMEN1 | |
| SCHEMBL19531503 | 0.80 | KDM6B (0.72) | CYP2C9HIF1AKDM6BTHRBMEN1 | |
| Diotyrosine SCHEMBL147579 | 0.79 | SIRT5 (0.82) | SIRT5CYP2C9THRBMEN1KMT2A | |
| Diotyrosine SCHEMBL147578 | 0.79 | SIRT5 (0.82) | SIRT5CYP2C9THRBMEN1KMT2A | |
| Diotyrosine SCHEMBL838215 | 0.79 | SIRT5 (0.82) | SIRT5CYP2C9THRBMEN1KMT2A | |
| Diotyrosine SCHEMBL1741366 | 0.78 | SIRT5 (0.79) | SIRT5CYP2C9THRBMEN1KMT2A | |
| Diotyrosine SCHEMBL14484740 | 0.78 | SIRT5 (0.79) | SIRT5CYP2C9THRBMEN1KMT2A | |
| Diotyrosine SCHEMBL31135680 | 0.78 | SIRT5 (0.79) | SIRT5CYP2C9THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
| US-20230159979-A1 | TRANSDUCERS, NANOPARTICLE TRANSDUCER DEVICES AND SYSTEMS, AND RELATED METHODS OF USE | UNIVERSITY OF WASHINGTON (US) | 2023-05-25 | — | — | US | disclosed |
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | PCR TECHNOLOGY HOLDINGS, LC (US) | 2018-11-13 | — | — | US | disclosed |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2016-10-06 | — | — | US | disclosed |
| EP-3068495-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | US CosmeceuTechs LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073769-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | US COSMECEUTECHS LLC (US) | 2015-05-21 | — | — | WO | disclosed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | RARA, LRAT, RARG | SIRT5 2288/4885CYP2C9 837/4885CYP2C19 1089/4885 |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | SIRT5 2254/4885CYP2C9 527/4885CYP2C19 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.